Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,899.60
(
0.11%
)
Dow Jones
49,149.38
(
-0.60%
)
Brent Oil
93.65
(
-1.44%
)
Bitcoin
77,993.29
(
2.18%
)
News Focus
News Focus
Post# of 447426
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

HDGabor

Send PM Follow Ignore
Followers 142
Posts 8676
Boards Moderated 0
Alias Born 10/07/2013

HDGabor

Re: PSea post# 167206

Saturday, 12/15/2018 10:01:07 AM

Saturday, December 15, 2018 10:01:07 AM

Post# of 447426
P-

I wonder if you are following Amarin … JT, Nov 1, 2018

I will mention as an aside that following the failed ASCEND study of Lovaza, it's our understanding that in Europe there is some questioning going on by regulatory authorities as to whether [indiscernible] should continue to be approved in Europe giving that failed study which was funded by the British - The Heart Institute.

Best,
G

"There are some things money can't buy. For everything else, there's AMRN."

Disclosure: I am long with this stock. I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News